Siamopoulos K C, Elisaf M, Dardamanis M, Sferopoulos G, Pappas M
Department of Internal Medicine, University of Ioannina, Greece.
J Cardiovasc Pharmacol. 1992;19 Suppl 3:S87-9.
The safety and efficacy of isradipine as well as its long-term effects on renal hemodynamics were evaluated in a study of 17 patients with mild-to-moderate essential hypertension and normal or slightly impaired renal function. After a 4-week placebo period, isradipine was administered according to a schedule of increasing dosages ranging from 1.25 to 5 mg twice daily. During treatment and at the latest follow-up (at 6 months), isradipine was found to lower blood pressure (diastolic and systolic) significantly. There were no significant side effects or changes in blood chemistry during treatment. Plasma renin activity and serum aldosterone were slightly raised whereas the glomerular filtration rate, renal plasma flow, and filtration fraction were significantly raised at the latest follow-up compared with the pretreatment levels.
在一项针对17例轻度至中度原发性高血压且肾功能正常或轻度受损患者的研究中，评估了伊拉地平的安全性、有效性及其对肾血流动力学的长期影响。在为期4周的安慰剂期后，按照每日两次、剂量从1.25毫克至5毫克递增的方案给予伊拉地平。在治疗期间及最新一次随访（6个月时），发现伊拉地平能显著降低血压（舒张压和收缩压）。治疗期间未出现显著副作用或血液生化指标变化。与治疗前水平相比，最新一次随访时血浆肾素活性和血清醛固酮略有升高，而肾小球滤过率、肾血浆流量和滤过分数则显著升高。
